Gennaio-Febbraio 2013, Vol. 48, N. 1 Riv Psichiatr 2013;48(1):1-9 | doi 10.1708/1228.13610 Scarica il PDF (127,1 kb) Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse titolo - split_articolo,controlla_titolo - art_titolo Negative dimension in psychiatry. Amotivational syndrome as a paradigm of negative symptoms in substance abuse title - controlla_titolo - art_title Dimensioni negative in psichiatria. La sindrome amotivazionale quale paradigma di sintomi negativi nell’abuso di sostanze autori - vau_aut_id LUCA ROVAI1, ANGELO GIOVANNI ICRO MAREMMANI1,2, MATTEO PACINI2, PIER PAOLO PANI4,FABIO RUGANI1, FRANCESCO LAMANNA2,3, ELISA SCHIAVI1, SALVATORE MAUTONE1,4,LILIANA DELL’OSSO1, ICRO MAREMMANI1,2 affiliazione_autori - ignora E-mail: email@example.com 1Department of Psychiatry NFB, University of Pisa2G. De Lisio Institute of Behavioural Sciences, Pisa3Addiction Treatment Unit (SerT), Pisa4Addiction Treatment Unit (SerT), Sant’Assenio, Salerno riassunto - art_riassunto summary. Negative symptoms, conceptualized as clinical manifestations of schizophrenia, and subsequently described in other psychiatric disorders, include the loss of normal arousal, drive and affective reactivity. In the field of substance abuse, an interesting analogy can be detected between negative symptoms, in their classical meaning, and the amotivational syndrome (AS), which has been described as a form of chronic cannabis intoxication. AS also shows a close resemblance to the reward deficiency syndrome (RDS) of alcoholics and stimulant abusers, and to the post-withdrawal syndrome (PWS) of detoxified heroin addicts. A variety of substances share a common tropism for the dopaminergic system, leading to a state of hypophoria, which seems to represent a common pathway for chronic substance abusers. In the light of these convergences, a common treatment principle for addictive disorders can be enunciated. This consists in resorting to pro-dopaminergic drugs, that are supposed to replace damaged functions and control craving, and in avoiding anti-dopaminergic drugs, that are expected to exacerbate craving and impede the reversal of the reward deficiency. parolechiave - lingua - vke_key_id key wokds: negative symptoms, amotivational syndrome, reward deficiency syndrome, hypophoria. abstract - art_abstract riassunto. I sintomi negativi, concettualizzati nell’ambito della schizofrenia, e successivamente riscontrati in altri disturbi psichiatrici, comprendono la perdita dei normali livelli di attivazione, iniziativa e affettività. Nel campo del disturbo da uso di sostanze esiste una analogia tra sintomi negativi, intesi nella loro accezione classica, e sindrome amotivazionale (SA), specifica dell’intossicazione cronica da cannabinoidi. A sua volta la SA mostra strette relazioni con la sindrome da deficit di reward, descritta negli alcolisti e nell’uso di psicostimolanti, e con la sindrome d’astinenza post astinenziale (SAPA) descritta per la dipendenza da eroina. Sostanze d’abuso diverse mostrano, dunque, una azione comune che converge sul sistema dopaminergico conducendo a uno stato di ipoforia. Alla luce di questa convergenza appare indicato, nel trattamento a lungo termine della dipendenza da sostanze, l’impiego di farmaci psicotropi dopaminergici che sostengano il sistema del renard, e controindicato all’opposto l’impiego di neurolettici, che lo antagonizzino. keyword - lingua - vke_key_id parole chiave: sintomi negativi, sindrome amotivazionale, sindrome da deficit di reward, ipoforia. testo - art_testo NEGATIVE DIMENSIONS IN PSYCHIATRY Negative psychiatric symptoms were originally conceptualized as part of one of the two major psychoses, schizophrenia. That cluster of features corresponds to the loss of normal arousal, drive and affective reactivity. In other words, they represent what the patient is lacking, and thus stand opposite to positive symptoms, which loom as something in excess, or in addition to normal functions, both as regards perceptions (hallucinations) and thought (delusions). On the whole, negative symptoms can be summed up as a state of detachment and disengagement from the environment. The development of negative symptoms starts early in the course of schizophrenia, proceeds gradually and is often associated with typical depressive symptoms, eventually resulting in a state of affective numbing and flattening of emotions that gives a poor response to pharmacological treatment (1). Later on, negative symptoms have been conceptualized as a dimension featured by different disorders. As a result, interest rose in the evaluation of negative symptoms within the clinical picture of bipolar disorders and obsessive-compulsive disorders, and also in degenerative neurological disorders such as dementia and Parkinson’s disease, and vascular-related damage (stroke) (2,3). Moreover, researchers have been looking further into the difference between negative symptoms and concurrent features of cognitive impairment, so that the concept of “negative” functioning has extended to embrace negative affects and cognitive deficiencies (4,5). Several authors have pointed out that some symptoms, such as apathy, abulia, anhedonia and social isolation are shared by depression and schizophrenia (6,7): this overlap between two major psychotic conditions suggests that negative symptoms are an expression of a general psychotic process rather than a specific feature of either clinical picture (8,9). In any case, negative symptoms show a different response to pharmacological treatment: the introduction of antidepressant treatment following the discontinuation of neuroleptic medication is followed by a sharper reduction of negative symptoms in depression affecting schizophrenic patients (10). In major depression, which, in comparison with other mood disorders, mostly features negative symptoms, those symptoms weigh as negative prognostic factors, especially as regards affective indifference, the sensation of an empty brain (thoughtlessness), and lack of drive (abulia) (11). Negative symptoms and cognitive impairment have also been reported in pictures of pathological grief, which, on clinical grounds, stands half way between depression and post-traumatic stress disorder, but is classified as an autonomous disorder (12). Pathological grief can follow the loss of a significant other through the dynamics of attachment (13); it also features avoidance and mumbling as a consequence of a reduced ability to elaborate the body of information that is associated with the loss that has been experienced (14,15). As far as negative symptoms are concerned, pathologic grief is characterized by social and job-related impairment (16). In particular, the reduction of memory is greater in pathological grief than in depression or post-traumatic stress disorder (17). Memory impairment has also been described in the obsessive-compulsive disorder, together with the disturbance of procedural functioning which is surely implied by that condition. Memory appears to be hampered as a consequence of the abnormal arrangement and the encoding of information at an output level. The most common cognitive features of this type are the prolonged latency of answers, the perseverance of wrong reactions to stimuli, and the awkwardness of adaptation to change on the basis of registered feedbacks (18). Such abnormalities were mapped as pertinent to the function of the frontal lobes and basal ganglia (19). In the field of substance-use disorders, an interesting analogy stands out between classic negative symptoms and the amotivational syndrome (AS) displayed as an expression of chronic cannabis intoxication. We will mainly focus on the AS and its links with the reward deficiency syndrome (RDS), originally described as a sequela of chronic alcohol and stimulant abuse. These two latter conditions are closely related too to the post-withdrawal syndrome (PWS) described by Martin and colleagues as an enduring pathologic state in abstinent detoxified opiate addicts (20-22). Bearing in mind the AS model, some of its prominent negative symptoms can be hypothesized as constituting a common endpoint of late clinical pictures linked to chronic intoxication by various substances of abuse. AMOTIVATIONAL SYNDROME AND ITS NEUROBIOLOGICAL BASES AS is one major complication of chronic exposure to cannabis, and combines the flattening of affects and elements of cognitive impairment similar to those displayed in schizophrenia and depression. It is characterized by gradual detachment from the outer world, and loss of emotional reactivity, drives and aims. Responsiveness to outer stimuli is blunted, and subjects are unable to experience or anticipate any pleasure except by using cannabis. Memory and attention are hampered (23) (Table 1). Affected subjects have a poor level of school-related functioning, are less satisfied with their educational activities, and easily enter into conflict with scholastic authorities. Both cannabis consumption itself and a cannabis-related environment are thought to contribute to the cognitive profile of AS (24). A body of research has shown that the acute administration of tetrahydrocannabinoid (THC) increases metabolism in the ventral tegmental area by a CB1-mediated input, and causes an increase in dopamine release to the shell area of the nucleus accumbens (25-27). This phenomenon has recently been confirmed in vivo in the human striatum by studies of functional neuroimaging that apply the positron emission tomography technique (28). Marijuana use increases blood-oxygen level dependence (29), which is related to a magnetic measurement of changes in the level of blood oxygen, and corresponds to various states of metabolic activation of specific brain areas engaged in the production of certain feelings or outputs. Two different cannabinoid receptors have been described in the human body. The CB1 type (30) is widespread in basal ganglia, the cerebellum and the hippocampus, and modulates the activity of the gabaergic, glutammatergic and dopaminergic systems, all of which are influenced by exposure to cannabis. By contrast, the CB2 type is expressed in the immune system (31). Both in the animal model and in man, continued exposure to cannabis causes a change in neuronal functioning (27,32,33). The acute increase in dopaminergic release is followed by a reduction of dopamine in the same areas of the reward system. This phenomenon is likely to be linked both to the down-regulation and the desensitization of CB1 receptors (27,34-36). On clinical grounds, these changes appear to be related to the development of anhedonia and a loss of sensitivity to previously pleasant stimuli (37,38). The application of functional magnetic resonance imaging succeeded in linking chronic exposure to cannabis to an altered reward sensitivity (34). Although dopamine is by far the most studied neurotransmitter in terms of the issue of reward and motivation, it should be recalled that dopaminergic pathways are influenced by other receptorial systems, and intermingle with both opioid and cannabinoid systems (39-44). On the whole, the AS, or cannabis-related RDS, may be directly related to a change in dopaminergic function, in this case through a cannabis-induced modulation of the cannabinoid receptor activity. SUBSTANCE USE AND REWARD-SYSTEM ACQUIRED ABNORMALITIES A well-known paradigm of acquired reward pathology is the natural history of heroin addiction. The course of heroin addiction develops in three stages (45): the first stage is pleasant involvement in substance use (the “honeymoon” stage). In healthy, non-tolerant subjects, acute opiate administration produces a marked state of euphoria, coupling serenity and peacefulness with actual mood elation and reward. At this stage, substance use does not take place on a regular basis, and people express confidence that they can break the habit at any time if so wished. No full-blown addictive behaviour is displayed, the substance is self-administered at stable doses, and the desire to use it is not very urgent or compelling. In most cases, withdrawal has not yet been experienced. The possible risks are underrated both by the person and the surrounding environment, although the first signs of mood instability and a lowered threshold for affective distress can be detected. The second stage follows the “honeymoon” one, and corresponds to the phenomenon of self-administration at increasing dosages: the transition to regular substance use leads to the development of tolerance, so that the euphoric effects dwindle, while the opposite, withdrawal-related feature starts to recur and becomes more and more prominent. In order to restore the balance and reproduce drug-elated euphoria, subjects automatically increase substance dosages, but in so doing they also pave the way for heavier rebound symptoms. The desire to self-administer the substance has now become urgent and overwhelming, despite the reduced persistence, intensity and frequency of satisfactory drug-induced euphoric states. Eventually, subjects swing away from a state of normal liability concomitant with recurrent states of withdrawal or discomfort on account of the absence of drug-induced euphoria. By this stage, the subject could be defined as a drug addict, because of his/her incapacity to change behaviour so as to reverse this undesirable condition and prevent relapses into it. Depending on a variety of factors, but especially as a result of the level most likely along the grade of addiction severity itself (craving, withdrawal) people get fully engaged in substance-seeking, by any available resource and by any means, no matter how hazardous or illegal it may be. The third stage is a series of stereotypically repeating cycles (the “revolving door” stage) featuring detoxification, temporary suspension of use with possible psychosocial recovery, addictive relapse and rapid impairment. At this stage, due to the increased difficulty of finding regular and consistent amounts of the substance, and to feelings of desperation about one’s general condition, addicts resort to treatment facilities. What can be noted at this point is the “clean” part of the revolving door cycle, from an addictive viewpoint, in a way that is able to reverse tolerance and so cut down on drug-related expenses. At this juncture, a new cycle is ready to begin, contrary to the subject’s expectation of being able to handle drug use from a condition in which craving is reset. Occasionally, deadly events interrupt the cycle, and this becomes more and more likely as cycles go by. Notably, the “clean”, non-tolerant periods bear the highest risk of overdose-related deaths, especially when they are spent in artificial environments (46). Within the framework of these three stages, the hedonistic-euphoric dimension, which was prominent at the beginning, is gradually replaced by a counterpolar state, characterized by anhedonia and hypophoria (lack of drive, motivation and reactivity with respect to what the person regards as being satisfactory). From a withdrawal-related point of view, through each detoxification cycle the patient passes from the acute withdrawal state (counterpolar to intoxication) to a later and enduring drug-free state featuring symptoms of hypophoria, looming as an acquired discomfort related to the absence of drug-related stimulation. Hypophoria includes somatic, vegetative and mental symptoms such as susceptible or irritable mood, amplified pain perception, inability to perform simple tasks and make normal efforts, and inability to experience reward in any way other than substance use. This syndrome closely resembles the subthreshold symptoms of dysthymia and the residual symptoms of chronic bipolar disorder (47). In conclusion, the natural history of heroin addiction displays three stages, eventually leading to a chronic state of hypophoria, possibly interrupted by relapses, which recalls the features of the RDS described as a sequela of alcohol and stimulant chronic abuse (45). From a neurophysiological point of view, a variety of substances are involved in the dynamics of pleasure-feeling and reward, among which dopamine, gaba and opioids are the best known. Anatomic sites of pleasure-feeling and reward-seeking seem to correspond to brain areas known as the ventral tegmental area, the nucleus accumbens, caudate, and substantia nigra. Dopaminergic activity is concentrated in the accumbens, caudate and ventral tegmental area, which are referred to as the afferent arm of reward circuitry. Gabaergic activity, which has been shown to be considerable in the ventral tegmental area, and opioidergic activity in the substantia nigra and accumbens, also contribute to reward dynamics. Basic neurochemical events that correspond to reinforcement and reward take place in the brain areas just named (48-50). Substances of abuse act upon specific receptors on neuronal cells, often mimicking the effect of endogenous equivalents. Thus, substance-inducing acute effects can be described as the stimulation of neuronal circuits corresponding to their endogenous equivalent. A number of studies (resorting to pharmacological parameters, neuroimaging, and microdialisis) have agreed on the fact that the acute administration of rewarding drugs causes a release of dopamine due to the projection of neurons with a cell body located in the ventral tegmental onto the post-synaptic surfaces of the nucleus accumbens, especially at the shell part level (51-53). This process normally takes place when people are exposed to salient stimuli, and underlies the dynamics of adaptation and selection of available sources of euphoric self-stimulation in one’s natural environment. An increased availability of dopamine in the pre-synaptic gasp of the accumbens shell builds a memory of salience for certain stimuli, which are functionally related to survival, nutrition, reproduction, or relief, through such feelings as sexual arousal, competition, appetite or discomfort (54-56). In other words, salience is a basic way to bookmark rewarding stimuli as crucial to attaining one’s aims sooner or to getting spatially closer to craved objects. As far as substance use is concerned, salience is the crucial node between the acute experience of substance-related effects and expected rewards from new episodes of consumption. Pleasant side-effects, environments and situations which happen to be associated with substance availability are registered as conditioning stimuli, so that they can cause reflected withdrawal and automatic drug-seeking behaviors, even in the absence of a direct craving for drug-related effects (57). This learning process corresponds to changes in the structure of the brain (gene expression, neuronal structure and morphology) by the mechanisms of neuronal plasticity, particularly in memory-related areas (58-61). Experimental research consistently indicates how such changes persist in the long term (62-65). These areas become sensitized to the presentation of drug-related stimuli, both in the animal model and in man, and they maintain that acquired sensitivity long after the latest exposure to the drug (62,65,66). Although dopamine release in the accumbens shell plays a crucial role in associative learning, other brain areas too are involved in the development of addiction starting from substance use. In particular, the anterior cingulated and orbito-frontal cortices at a prefrontal level mediate behavioural outputs produced by drug-related cues (67-70). Neuroimaging studies have clearly mapped the metabolic changes in specific areas associated with subjective craving and drug-related cueing: the extent of metabolic changes in the orbito-frontal and anterior cingulated cortex areas is directly related to the intensity of cue-induced craving (69,71-76). On the other hand, neuroimaging studies on brains of abstinent individuals with a history of chronic addictive use reveals a reduced level of baseline metabolism in the same areas (73,76-81). Such metabolic “depression” also includes responses to normal biologically relevant stimuli, such as food-related or sexual cues (68) and to decision-making challenges in certain experimental settings (82,83). In the striatum, both a lower level of available dopamine and a reduced number of D2 receptors have been documented (84-88). To sum up, chronically exposed individuals who have developed drug addiction show they are hypersensitive to drug-related stimuli, while they are less responsive to other sources of direct stimulation or cueing. Other systems are relevant to addiction biology, such as the hypothalamic-pituitary-adrenal axis (HPA), which mediates response to stress. Substances of abuse stimulate the HPA axis, which can itself become involved in the process of reward and reinforcement of self-administration (89,90). Moreover, substance abuse and withdrawal are linked to the production and release of the corticotropin releasing factor (CRF) by extra-hypothalamic sites (91-94). Stressing stimuli may increase extra-hypothalamic CRF-producing activity, thus amplifying the reinforcing effects of drugs, appetition for them and addictive behaviours (95,96). It has also been documented that CRF-like factors are related to acute and long-term withdrawal, and to relapse proneness, along with the known clinical link between the low threshold to subjective stress and relapses in abstinent drug addicts (93,97-99). On the whole, the dopaminergic system plays a crucial role in substance abuse and addiction. A number of research papers have indicated how cannabis, as well as other substances of abuse, share a dopamine-releasing action in the nucleus accumbens (the main node of the dopaminergic mesolimbic pathway) (27,51,100-104). Likewise, THC and other drugs (amphetamines, cocaine, alcohol, nicotine and heroin) share the property of selectively increasing dopamine release in the shell part of the accumbens, rather than its core (27,39,52,105,106). Alcohol has proved to increase dopaminergic pulsatility and a generalized increase in arousal and sensitivity to reward (76). Chronic cocaine use is also responsible for a reduced dopaminergic release in the accumbens (107). Since all the different substances seem to share a common mechanism of action, they may be thought to share the feature of eventual damage too. Bowirrat et al. (108) argue that dopamine is the main neurotransmitter responsible for both the reward cascade common to all substances of abuse, and the AS: reduced dopaminergic activity underlies all conditions of chronic alcohol or drug administration, which correspond to reduced sensitivity to reward and decreased ability to cope with stress. Different substances own one specific neurochemical property linked to their direct molecular target (i.e. the cannabinoid system, gabaergic receptors for alcohol and benzodiazepines, the opioidergic system, cholinergic receptors for nicotine) and a common eventual effect on the dopaminergic system, with special regard to the reward pathway circuitry (108). There is therefore no justification for using the concept of the AS or RDS to indicate one specific condition (chronic cannabis use), but a common clinical ground for all kinds of chronic abuse. One could also hypothesize that the rewards of drug users are already impaired before drug use, on the basis of genetic dispositions to drug use, possibly involving the polymorphism of DRD2 receptors, a key element in the reward cascade (109). Blum et al. (23,110) have suggested that cannabis abusers may be characterized by a primary abnormality of the reward system, with a lower level of dopaminergic activity, which becomes normalized through exposure to cannabis. This view recalls the self-medication hypothesis of addictive disorders originally formulated by Khantzian (111) with respect to the addictive use of opiates and cocaine: in that case, specific emotional distress and mental disorders were hypothesized as the basis for involvement in regular drug use with a self-medicating purpose. THERAPEUTIC IMPLICATIONS On therapeutic grounds, AS, RDS and PWS, all developing as late consequences of intensive drug use, achieve stability through a reduced dopaminergic metabolism in the reward system circuitry, and require the employment of specific-agonist drugs (opioidergic, cholinergic, gabaergic) and counterindicate the employment of functional antagonists of the reward-related dopaminergic system, for the purpose of reward rebalance. In other words, therapeutic medications should interact with the same targets as those of abused drugs, at a neurochemical level, in order to replace damaged physiological functions. In the case of heroin addiction, for instance, methadone treatment can be seen as providing a general paradigm: methadone does replace impaired functions and prevents the PWS, does not impede the reprise of the dopaminergic metabolism and prevents further damage by the mechanism of narcotic blockade. Drugs like varenicline (cholinergic agonist) (112) and bupropion (cholinergic antagonist but dopamine agonist) (113,114) have been tried with some success in the treatment of nicotine withdrawal and nicotine dependence. Unlike varenicline, bupropion is not specific to nicotine, but acts upon the common reward pathway: its dopaminergic and noradrenergic actions are responsible for nicotine withdrawal symptoms and favour detachment from nicotine, although bupropion is not powerful in keeping craving under control in the longer term; at least at tolerated dosages, bupropion looms as the paradigm of dopaminergic agents and is capable of producing positive effects in drug abuse, regardless of a specific anticraving action, because of its action on the shared ground of a reduced dopamine-related function. By contrast, the use of neuroleptic drugs should be applied with great caution in patients with a history of reward impairment, since they own a sharp dopamine-antagonist action. Atypical antipsychotics, despite their different profile of neurochemical action, may elicit or worsen reward impairment, though to a lesser extent, or interfere with dopamine metabolism by different pathways (115). Even if their use is recommended with respect to acute psychosis, those with low affinity and specificity (fast-off interaction dynamics from dopamine receptors) are preferable (116). CONCLUSIONS A variety of substances of abuse, despite their different mechanisms of action, converge on a common pathway centring on the circuitry of reward. The eventual damage produced by all substances involves dopaminergic dysfunction, mirroring the initial dopaminergic stimulation corresponding to euphoria and increased reward. In the case of cannabis, this picture has been described as the AS. Adopting a longitudinal view, the course of addiction starts from the experience of hyperstimulation and this proceeds to overcoming dysphoria and loss of motivation. Deep changes in brain function and microscopic structure underlie these clinical grounds, and correspond to the concept of addiction as a unique metabolic disease, regardless of the meaning and clinical picture or earlier phases. The abnormal dopaminergic metabolism of the addictive brain implies the impairment of general reward capacity, also involving the same substance responsible for addiction, together with the ability to cope with stress and the lack of continuous stimulation. We have tried to give a comprehensive description of the cannabis-related AS, the alcohol/cocaine-related RDS and the opioid-related PWS. These three clinical pictures, originally referred to three different classes of substances, share the feature of motivational loss, which looms as the specific acquired functional leak affecting the addict’s brain. On therapeutic grounds, pro-dopaminergic drugs are to be regarded as useful, because of their positive impact on the hypotrophic dopaminergic system, while anti-dopaminergic drugs are to be avoided if possible, especially in long-term regimens. biblio_titolo - ignora REFERENCES bibliografia - art_bibliografia 1. Hafner H, Loffler W, Maurer K, Hambrecht M, an der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 1999; 100: 105-18. 2. Milak MS, Aniskin DB, Eisenberg DP, et al. The negative syndrome as a dimension: factor analyses of PANSS in major depressive disorder and organic brain disease compared with negative syndrome structures found in the schizophrenia literature. Cogn Behav Neurol 2007; 20: 113-20. 3. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson’s disease. Brain Res Bull 2006; 70: 312-21. 4. Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 1998; 13 Suppl 3: S21-6. 5. O’Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC. Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 2000; 12: 4-15. 6. Sax KW, Strakowski SM, Keck PE Jr., Upadhyaya VH, West SA, McElroy SL. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry 1996; 168: 68-71. 7. Gerbaldo H, Fickinger MP, Wetzel H, Helisch A, Philipp M, Benkert O. Primary enduring negative symptoms in schizophrenia and major depression. J Psychiatr Res 1995; 29: 297-302. 8. Toomey R, Faraone SV, Simpson JC, Tsuang MT. Negative, positive, and disorganized symptom dimensions in schizophrenia, major depression, and bipolar disorder. J Nerv Ment Dis 1998; 186: 470-6. 9. Maziade M, Roy MA, Martinez M, et al. Negative, psychoticism, and disorganized dimensions in patients with familial schizophrenia or bipolar disorder: continuity and discontinuity between the major psychoses. Am J Psychiatry 1995; 152: 1458-63. 10. Lewine RR. A discriminant validity study of negative symptoms with a special focus on depression and antipsychotic medication. Am J Psychiatry 1990; 147: 1463-6. 11. Chaturvedi SK, Sarmukaddam SB. Prediction of outcome in depression by negative symptoms. Acta Psychiatr Scand 1986; 74: 183-6. 12. Bonanno GA, Neria Y, Mancini A, Coifman KG, Litz B, Insel B. Is there more to complicated grief than depression and posttraumatic stress disorder? A test of incremental validity. J Abnorm Psychol 2007; 116: 342-51. 13. Shear K, Shair H. Attachment, loss, and complicated grief. Dev Psychobiol 2005; 47: 253-67. 14. Shear K, Monk T, Houck P, et al. An attachment-based model of complicated grief including the role of avoidance. Eur Arch Psychiatry Clin Neurosci 2007; 257: 453-61. 15. Stroebe M, Boelen PA, van den Hout M, Stroebe W, Salemink E, van den Bout J. Ruminative coping as avoidance: a reinterpretation of its function in adjustment to bereavement. Eur Arch Psychiatry Clin Neurosci 2007; 257: 462-72. 16. Prigerson HG, Frank E, Kasl SV, et al. Complicated grief and bereavement-related depression as distinct disorders: preliminary empirical validation in elderly bereaved spouses. Am J Psychiatry 1995; 152: 22-30. 17. Boelen PA, Huntjens RJ, van Deursen DS, van den Hout MA. Autobiographical memory specificity and symptoms of complicated grief, depression, and posttraumatic stress disorder following loss. J Behav Ther Exp Psychiatry 2010; 41: 331-7. 18. Olley A, Malhi G, Sachdev P. Memory and executive functioning in obsessive-compulsive disorder: a selective review. J Affect Disord 2007; 104: 15-23. 19. Kuelz AK, Hohagen F, Voderholzer U. Neuropsychological performance in obsessive-compulsive disorder: a critical review. Biol Psychol 2004; 65: 185-236. 20. Martin WR. Pathophysiology of narcotic addiction: possible role of protracted abstinence in relapse. In: Zarafonetis CJD (ed). Drug abuse. Philadelphia: Lea and Febiger, 1972. 21. Martin WR, Hewett BB, Baken AJ, Heartzen CA. Aspects of the psychopathology and pathophysiology of addiction. Drug Alcohol Depend 1977; 2: 185-202. 22. Martin J, Ingles J. Pain tolerance and narcotic addiction. Br J Soc Psychol 1965; 4: 224-9. 23. Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 2000; 32: 1-112. 24. Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. Addiction 2000; 95: 1621-30. 25. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997; 8: 649-52. 26. Gardner EL, Vorel SR. Cannabinoid transmission and reward-related events. Neurobiol Dis 1998; 5: 502-33. 27. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms. A review of recent preclinical data. Psychopharmacology (Berl) 2003; 169: 115-34. 28. Bossong MG, van Berckel BN, Boellaard R, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759-66. 29. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. Marijuana craving in the brain. Proc Natl Acad Sci U S A 2009; 106: 13016-21. 30. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13. 31. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5. 32. Gardner EL. Addictive potential of cannabinoids: the underlying neurobiology. Chem Phys Lipids 2002; 121: 267-90. 33. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 1996; 6: 243-51. 34. van Hell HH, Vink M, Ossewaarde L, Jager G, Kahn RS, Ramsey NF. Chronic effects of cannabis use on the human reward system: an fMRI study. Eur Neuropsychopharmacol 2010; 20: 153-63. 35. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47 Suppl 1: 345-58. 36. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003; 15: 91-119. 37. Bovasso GB. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001; 158: 2033-7. 38. Janiri L, Martinotti G, Dario T, et al. Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study. Neuropsychobiology 2005; 52: 37-44. 39. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common m1 opioid receptor mechanism. Science 1997; 276: 2048-50. 40. Tanda G, Loddo P, Di Chiara G. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 1999; 376: 23-6. 41. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoid and reduced addictive effects of opiates in CBI receptor knockout mice. Science 1999; 283: 401-4. 42. Navarro M, Carrera MR, Fratta W, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001; 21: 5344-50. 43. Zimmer A, Valjent E, Konig M, et al. Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J Neurosci 2001; 21: 9499-505. 44. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002; 22: 1146-54. 45. Maremmani I, Castrogiovanni P. Disturbi da uso di sostanze. Disturbi da oppiacei ed analgesici. In: Cassano GB, et al. (eds). Trattato Italiano di Psichiatria. Volume 2 (43). Milano: Masson, 1992. 46. Maremmani I, Pacini M. Understanding the pathogenesis of drug addiction in order to implement a correct pharmacological intervention. Heroin Addict Relat Clin Probl 2003; 5: 5-12. 47. Akiskal HS, Judd LL, Gillin JC, Lemmi H. Subthreshold depressions: clinical and polysomnographic validation of dysthymic, residual and masked forms. J Affect Disord 1997; 45: 53-63. 48. Bozarth MA, Wise R. Heroin reward is dependent on a dopaminergic substrate. Life Sci 1981; 29: 1881-6. 49. Karler R, Calder L, Thai L, Bedingfield B. A dopaminergic-glutamatergic basis for the action of amphetamine and cocine Brain Res 1994; 658: 8-14. 50. Roberts DC, Ranaldi R. Effect of dopaminergic drugs on cocaine reinforcement. Clin Neuropharmacol. 1995; 18: S84-S95. 51. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274-378. 52. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the “shell” as compared with the “core” of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995; 92: 12304-8. 53. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 81-96. 54. Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 2002; 22: 3306-11. 55. Berridge KC. The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007; 191: 391-431. 56. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005; 162: 1414-22. 57. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162: 1403-13. 58. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res 1997; 25: 192-216. 59. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2001; 96: 103-14. 60. Carlezon WA, Nestler EJ. Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? Trends Neurosci 2002; 25: 610-5. 61. Vezina P. Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci Biobehav Rev 2004; 27: 827-39. 62. Nestler EJ. Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem 2002; 78: 637-47. 63. Bolaños CA, Nestler EJ. Neurotrophic mechanisms in drug addiction. Neuromolecular Med 2004; 5: 69-83. 64. Carlezon WA, Konradi C. Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 2004; 47: 47-60. 65. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem 2002; 78: 610-24. 66. Robbins TW, Everitt BJ. Limbic-striatal memory systems and drug addiction. Neurobiol Learn Mem 2002; 8: 625-36. 67. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O’Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999; 156: 11-8. 68. Garavan H, Pankiewicz J, Bloom A, et al. Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli Am J Psychiatry 2000; 157: 1789-98. 69. Wexler BE, Gottschalk CH, Fulbright RK, et al. Functional magnetic resonance imaging of cocaine craving. Am J Psychiatry 2001; 158: 86-95. 70. Wang GJ, Volkow ND, Fowler JS, et al. Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sci 1999; 64: 775-84. 71. Grant S, London ED, Newlin DB, et al. Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci U S A 1996; 93: 12040-5. 72. Maas LC, Lukas SE, Kaufman MJ, et al. Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving. Am J Psychiatry 1998; 155: 124-6. 73. Volkow ND, Fowler JS, Wolf AP, et al. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry 1991; 148: 621-6. 74. Breiter HC, Gollub RL, Weisskoff RM, et al. Acute effects of cocaine on human brain activity and emotion. Neuron 1997; 19: 591-611. 75. Volkow ND, Wang GJ, Fowler JS, et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 1999; 156: 19-26. 76. Volkow ND, Wang GJ, Ma Y, et al. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 2003; 23: 11461-8. 77. Volkow ND, Hitzemann R, Wang GJ, et al. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 1992; 11: 184-90. 78. Volkow ND, Hitzemann R, Wang GJ, et al. Decreased brain metabolism in neurologically intact healthy alcoholics. Am J Psychiatry 1992; 149: 1016-22. 79. Volkow ND, Wang GJ, Hitzemann R, et al. Recovery of brain glucose metabolism in detoxified alcoholics. Am J Psychiatry 1994; 151: 178-83. 80. Volkow ND, Wang GJ, Overall JE, et al. Regional brain metabolic response to lorazepam in alcoholics during early and late alcohol detoxification. Alcohol Clin Exp Res 1997; 21: 1278-84. 81. Catafau AM, Etcheberrigaray A, Perez de los Cobos J, et al. Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification. J Nucl Med 1999; 40: 19-24. 82. Kaufman JN, Ross TJ, Stein EA, Garavan H. Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging. J Neurosci 2003; 23: 7839-43. 83. Forman SD, Dougherty GG, Casey BJ, et al. Opiate addicts lack error-dependent activation of rostral anterior cingulate Biol Psychiatry 2004; 55: 531-7. 84. Volkow ND, Fowler JS, Wolf AP, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990; 147: 719-24. 85. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993; 14: 169-77. 86. Wang GJ, Volkow ND, Fowler JS, et al. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 1997; 16: 174-82. 87. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-82. 88. Volkow ND, Wang GJ, Telang F, et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J Neurosci 2007; 27: 12700-6. 89. Piazza PV, Le Moal M. The role of stress in drug self-administration. Trends Pharmacol Sci 1998; 19: 67-74. 90. Goeders NE. The impact of stress on addiction. Eur Neuropsychopharmacol 2003; 13: 435-41. 91. Richter R, Weiss F. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administration rats. Synapse 1999; 32: 254-61. 92. Sarnyai Z, Shaham Y, Heinrichs SC. The role of corticotropinreleasing factor in drug addiction. Pharmacol Rev 2001; 53: 209-43. 93. Weiss F, Ciccocioppo R, Parsons LH, et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann NY Acad Sci 2001; 937: 1-26. 94. Maj M, Turchan J, Smialowska M, Przewlocka B. Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. Neuropeptides 2003; 37: 105-10. 95. Cador M, Cole BJ, Koob GF, Stinus L, Le Moal M. Central administration of corticotropin releasing factor induces long-term sensitization to d-amphetamine. Brain Res 1993; 606: 181-6. 96. Stam R, Bruijnzeel AW, Wiegant VM. Long-lasting stress sensitisation. Eur J Pharmacol 2000; 405: 217-24. 97. Merlo Pich E, Lorang M, Yeganeh M, et al. Increase of extracellular corticotrophin releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995; 15: 5439-47. 98. Koob GF. Stress, corticotropin-releasing factor, and drug addiction. Ann NY Acad Sci 1999; 897: 27-45. 99. Koob GF. Neuroadaptive mechanisms of addiction: studies on the extended amygdala. Eur Neuropsychopharmacol 2003; 13: 442-52. 100. Prado-Alcala R, Wise RA. Brain stimulation reward and dopamine terminal fields. I. Caudate-putamen, nucleus accumbens and amygdala. Brain Res 1984; 297: 265-73. 101. Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely-moving rats by ethanol. J Pharmacol Exp Ther 1986; 239: 219-38. 102. Damsma G, Day J, Fibiger HC. Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol 1989; 168: 363-8. 103. Kuczenski R, Segal DS, Aizenstein ML. Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci 1991; 11: 2703-12. 104. Chang JY, Sawyer SF, Lee RS, Woodward DJ. Electrophysiological and pharmacological evidence for the role of the nucleus accumbens in cocaine self-administration in freely moving rats. J Neurosci 1994; 14: 1224-44. 105. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382: 255-7. 106. Benwell ME, Balfour DJ. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 1992; 105: 849-56. 107. Perez MF, Ford KA, Goussakov I, Stutzmann GE, Hu XT. Repeated cocaine exposure decreases dopamine D(2)-Like receptor modulation of Ca(2+) homeostasis in rat nucleus accumbens neurons. Synapse 2011; 65: 168-80. 108. Bowirrat A, Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet 2005; 132B: 29-37. 109. Blum K, Noble EP. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1994; 263: 2055-60. 110. Blum K, Wood RC, Braverman ER, Chen TJ, Sheridan PJ. The D2 dopamine receptor gene as a predictor of compulsive disease: Bayes’ theorem. Funct Neurol 1995; 10: 37-44. 111. Khantzian EJ. The self-medicatio hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142: 1259-64. 112. Crunelle CL, Miller ML, Booij J, van den Brink W. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol 2010; 20: 69-79. 113. Palmatier MI, Levin ME, Mays KL, Donny EC, Caggiula AR, Sved AF. Bupropion and nicotine enhance responding for nondrug reinforcers via dissociable pharmacological mechanisms in rats. Psychopharmacology (Berl) 2009; 207: 381-90. 114. Grieder TE, Sellings LH, Vargas-Perez H, et al. Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine. Neuropsychopharmacology 2010; 35: 943-54. 115. Danna CL, Elmer GI. Disruption of conditioned reward association by typical and atypical antipsychotics. Pharmacol Biochem Behav 2010; 96: 40-7. 116. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360-9. 117. Campbell I. The amotivational syndrome and cannabis use with emphasis on the Canadian scene. Ann NY Acad Sci 1976; 282: 33-6.